1. Home
  2. GRAF vs ITOS Comparison

GRAF vs ITOS Comparison

Compare GRAF & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRAF
  • ITOS
  • Stock Information
  • Founded
  • GRAF 2021
  • ITOS 2011
  • Country
  • GRAF United States
  • ITOS United States
  • Employees
  • GRAF N/A
  • ITOS N/A
  • Industry
  • GRAF
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GRAF
  • ITOS Health Care
  • Exchange
  • GRAF NYSE
  • ITOS Nasdaq
  • Market Cap
  • GRAF 294.4M
  • ITOS 381.2M
  • IPO Year
  • GRAF 2024
  • ITOS 2020
  • Fundamental
  • Price
  • GRAF $10.46
  • ITOS $10.26
  • Analyst Decision
  • GRAF
  • ITOS Hold
  • Analyst Count
  • GRAF 0
  • ITOS 6
  • Target Price
  • GRAF N/A
  • ITOS $10.60
  • AVG Volume (30 Days)
  • GRAF 6.5K
  • ITOS 764.9K
  • Earning Date
  • GRAF 01-01-0001
  • ITOS 08-07-2025
  • Dividend Yield
  • GRAF N/A
  • ITOS N/A
  • EPS Growth
  • GRAF N/A
  • ITOS N/A
  • EPS
  • GRAF 0.32
  • ITOS N/A
  • Revenue
  • GRAF N/A
  • ITOS $35,000,000.00
  • Revenue This Year
  • GRAF N/A
  • ITOS N/A
  • Revenue Next Year
  • GRAF N/A
  • ITOS N/A
  • P/E Ratio
  • GRAF $32.44
  • ITOS N/A
  • Revenue Growth
  • GRAF N/A
  • ITOS 177.89
  • 52 Week Low
  • GRAF $9.03
  • ITOS $4.80
  • 52 Week High
  • GRAF $11.02
  • ITOS $18.13
  • Technical
  • Relative Strength Index (RSI)
  • GRAF N/A
  • ITOS 66.97
  • Support Level
  • GRAF N/A
  • ITOS $10.05
  • Resistance Level
  • GRAF N/A
  • ITOS $10.21
  • Average True Range (ATR)
  • GRAF 0.00
  • ITOS 0.13
  • MACD
  • GRAF 0.00
  • ITOS -0.06
  • Stochastic Oscillator
  • GRAF 0.00
  • ITOS 81.48

About GRAF GRAF GLOBAL CORP

Graf Global Corp is a blank check company.

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Share on Social Networks: